PTRG-DES Consortium

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

13160 participants

Study Classification

OBSERVATIONAL

Study Start Date

2003-07-09

Study Completion Date

2020-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The PTRG-DES consortium is a coalition composed of multi-center, real-world registries including CAD patients treated with DES in South Korea. From 9 academic registries in Korea, a total of 13,160 patients were enrolled for this database between July 2003 and August 2018. The aim of the study was to investigate long-term prognostic implications of platelet function and genotypes after DES implantation for significant CAD in South Korea.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES

NCT02079194

Coronary Artery Disease

UNKNOWN NA

Comparison of 1 Month vs. 12 Months DAPT in Patients Undergoing PCI With Genoss® DES

NCT05770674

Coronary Artery Disease

RECRUITING NA

Genotyping Influences Outcome of Coronary Artery Stenting

NCT02707445

Myocardial Ischemia CLOPIDOGREL, POOR METABOLISM of (Disorder)

COMPLETED NA

Duration of Clopidogrel Therapy After Drug-Eluting Stent (DES-LATE)

NCT01186146

Coronary Artery Disease

COMPLETED PHASE4

Tailored Anti-platelet Therapy After DES Implantation in High-risk Patients

NCT05936606

Coronary Artery Disease

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators enrolled patients treated with DES during DAPT including clopidogrel who had at least one of VerifyNow test (PRU and ARU) and genotyping. In this consortium, the investigators tried to find the unique characteristics of East Asians based on platelet function, genotype and inflammatory markers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease Clopidogrel, Poor Metabolism of Platelet Dysfunction Stent Thrombosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PTRG-DES registry

After DES implantation, CAD patients were treated with DAPT with clopidogrel and aspirin. During hospitalization, their platelet function, genotype and inflammation biomarker were evaluated.

Clopidogrel Tablets

Intervention Type DRUG

DES-treated patients were treated with clopidogrel 75 mg daily and aspirin 100 mg daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Clopidogrel Tablets

DES-treated patients were treated with clopidogrel 75 mg daily and aspirin 100 mg daily

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

aspirin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Consecutive patients at every centre successfully treated with one or more DES approved by the US FDA or CE mark and who were adequately loaded with clopidogrel were eligible for enrolment, regardless of patient or lesion complexity.

Exclusion Criteria

* the occurrence of a major complication during the procedure or before platelet function testing, or if bypass surgery was planned after PCI.
* Any P2Y12 inhibitor other than clopidogrel
* PCI strategy other than DES
* Needed oral anticoagulant (e.g. atrial fibrillation)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No